Clinical Data Amgen scores with new thyroid eye disease formulation PharmaphorumCan Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 8, 2026) Pharmaphorum Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster? Clinical DataOphthalmologyRead full story Post navigation Previous: FDA floats new clinical trial reforms; Takeda punts Denali brain drugNext: Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
